PYC Therapeutics (ASX:PYC) said the US Food and Drug Administration has granted Rare Pediatric Disease (RPD) designation to its drug candidate VP-001 for treating retinitis pigmentosa type 11, a blinding childhood eye disease, according to a Monday filing with the Australian bourse.
Currently in phase 1/2 studies, VP-001 is set to enter a potentially registrational trial in 2025, the filing said.
The RPD designation supports the development of therapies for serious, rare pediatric conditions, the filing added.
Shares of the company fell almost 4% in recent Monday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。